US 12,171,756 B2
NLRP3 modulators
Daniel O'Malley, New Hope, PA (US); Ashvinikumar V. Gavai, Princeton Junction, NJ (US); Patrice Gill, Levittown, PA (US); Christine M. Tarby, Lawrenceville, NJ (US); Scott Hunter Watterson, Pennington, NJ (US); Hua Gong, King of Prussia, PA (US); David K. Williams, Delran, NJ (US); Shomir Ghosh, Brookline, MA (US); and William R. Roush, Tequesta, FL (US)
Assigned to INNATE TUMOR IMMUNITY, INC., Princeton, NJ (US)
Filed by Innate Tumor Immunity, Inc., Princeton, NJ (US)
Filed on Apr. 28, 2022, as Appl. No. 17/731,279.
Application 17/731,279 is a division of application No. 16/629,980, granted, now 11,344,543, previously published as PCT/US2018/041723, filed on Jul. 12, 2018.
Claims priority of provisional application 62/532,932, filed on Jul. 14, 2017.
Claims priority of provisional application 62/662,405, filed on Apr. 25, 2018.
Claims priority of provisional application 62/689,412, filed on Jun. 25, 2018.
Prior Publication US 2022/0257587 A1, Aug. 18, 2022
Int. Cl. C07D 401/10 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/501 (2006.01); A61K 31/5377 (2006.01); A61K 31/551 (2006.01); A61K 31/553 (2006.01); A61K 45/06 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01)
CPC A61K 31/4709 (2013.01) [A61K 31/496 (2013.01); A61K 31/501 (2013.01); A61K 31/5377 (2013.01); A61K 31/551 (2013.01); A61K 31/553 (2013.01); A61K 45/06 (2013.01); C07D 401/10 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01)] 10 Claims
 
1. A compound having formula (I), or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
W′ is H;
W is independently selected from:

OG Complex Work Unit Chemistry
R3 is independently pyrazolyl, thienyl or isothiazolyl;
R4 is independently H or F; and
Rf is independently H, CH2CH2OH, or —C(O)O(C1-4 alkyl).